A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years


Eligibility Criteria:
Inclusion Criteria:

* Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
* Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure.
* Written informed assent obtained from the subjects when applicable according to local requirements.
* A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1)
* Body weight ≥ 6 kg/13.23 pounds.
* A subject is eligible if they meet at least one of the following criteria:

  * Documented previous VZV vaccination OR
  * Medically verified varicella (with source documentation) OR
  * Seropositive for VZV prior to transplantation.
* Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1)
* Subject who has received an ABO compatible allogeneic renal transplant (allograft).
* Subject with stable renal function with stability defined as \<20% variability between the last two creatinine measurements or based on investigator opinion after review of multiple creatinine measurements.
* Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to randomization (Visit Day 1).
* Female subjects of childbearing potential may be enrolled in the study, if the subject

  * has practiced adequate contraception for 30 days prior to Visit Day 1 and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series

Exclusion Criteria:

Medical conditions

* Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft
* Evidence of recurrent primary kidney disease within the current allograft
* Previous allograft loss secondary to recurrent primary kidney disease
* History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted).
* Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment
* Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant
* VZV serostatus unknown prior to transplant
* Subjects with advanced chronic kidney disease
* Evidence of significant proteinuria (≥ 200 g/mol creatinine) believed to be of renal origin (an example of non-renal origin is proteinuria from mucus in a reconstructed bladder)
* Subjects without multiple dialysis options in the event acute or chronic dialysis needed.
* History of unstable or progressive neurological disorder.
* Subjects ≤ 5 years of age with a history of one or more simple or complex febrile seizures
* Subjects \> 5 years with history of one or more complex febrile seizures
* Occurrence of a varicella or HZ episode by clinical history within the 6 months (180 days) preceding Visit Day 1
* Any autoimmune disease, with the following exceptions which do not constitute an exclusion criterion:

  * IgA nephropathy
  * Rapidly progressive glomerulonephritis
  * Membranous glomerulonephritis
  * Idiopathic Type I membranoproliferative glomerulonephritis
  * Diabetes mellitus (type 1 and 2) with diabetic nephropathy
* Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency disease
* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
* Any condition which, in the judgement of the investigator would make intramuscular injection unsafe.
* Atypical Haemolytic Uraemic Syndrome.

Prior/Concomitant therapy

* Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned use during the study period.
* Subject in receipt of treatment for rejection during the six months (180 days) prior to enrolment.
* Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day 1 or planned administration during the duration of the study.
* Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned administration during the duration of the study.
* Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned administration of immunoglobulins during the duration of the study.
* Administration or planned administration of a vaccine within 30 days prior to Visit Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days prior to or 14 days after Visit Month 1.
* Previous vaccination against HZ
* Varicella vaccination within the 6 months (180 days) preceding Visit Day 1
* Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine

Prior/Concurrent clinical study experience

• Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product

* available locally through compassionate use programs,
* submitted for and pending local/country registration,
* approved and registered for use in other countries with well-documented Summary of Product Characteristics or Prescribing Information
* The name of the active component(s) of these immunosuppressants must be provided in the concomitant medication listing

Other exclusions

* Child in care
* Pregnant or lactating female
* Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) between one month (30 days) prior to Visit Day 1 through two months (60 days) after Visit Month 1.
* Evidence or high suspicion, in the opinion of the investigator, of non-compliance or non-adherence to use of induction and/or maintenance immunosuppressive therapies.
* Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit

  * Completion must cover the 7 days immediately prior to randomisation (Visit Day 1).
  * Completion is defined as a minimum of 6 days completed.
  * Subjects with less than 6 days completed may be offered a new date for Visit Day 1 and the opportunity to comply with the completion of the 7-day pre-vaccination diary card prior to the new planned Visit Day 1.
* Any study personnel or their immediate dependants, family, or household member.